Skip to main content
Premium Trial:

Request an Annual Quote

Invivoscribe Receives Regulatory Approval for FLT3 Mutation Assay in Japan

NEW YORK (GenomeWeb) – Invivoscribe announced today that it has received approval from Japan's Pharmaceuticals and Medical Devices Agency (PMDA)for its LeukoStrat CDx FLT3 Mutation Assay companion diagnostic.

The firm expects to begin shipments of the FTL3 assay from LabPMM GK, the assay's marketing authorization holder in Japan, in late 2018.

Invivoscribe's test is the first companion diagnostic for acute myeloid leukemia and detects internal tandem duplications and tyrosine kinase domain mutations D835 and I836 in the FLT3 gene. The tool includes software that interprets data, generates mutant and wildtype signal ratios for ITD and TKD mutations, and predicts response to the drug gilteritinib fumarate (Xospata).

Invivoscribe previously submitted a pre-market approval application for the assay to Japan's PMDA and as a panel track supplement to the US Food and Drug administration in May.

"Test standardization is a critical part of precision medicine as it helps to refine treatments and accelerate drug approvals," Invivoscribe CEO and CSO Jeffrey Miller said in a statement. "These [regulatory] milestones represent a significant step towards standardized detection of one of the most important driver mutations in AML."

Invivoscribe previously released a CE-marked IVD version of the LeukoStrat assay in August 2017.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more